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Abstract
Introduction Breast cancer subtypes exhibit different genomic
aberration patterns with a tendency for high-level amplifications
in distinct chromosomal regions. These genomic aberrations
may drive carcinogenesis through the upregulation of proto-
oncogenes. We have characterized DNA amplification at the
human chromosomal region 13q34 in breast cancer.
Methods A set of 414 familial and sporadic breast cancer cases
was studied for amplification at region 13q34 by fluorescence
in situ hybridization (FISH) analysis on tissue microarrays.
Defining the minimal common region of amplification in those
cases with amplification at 13q34 was carried out using an
array-based comparative genomic hybridization platform. We
performed a quantitative real-time - polymerase chain reaction
(qRT-PCR) gene expression analysis of 11 candidate genes
located within the minimal common region of amplification.
Protein expression levels of two of these genes (TFDP1 and
CUL4A) were assessed by immunohistochemical assays on the
same tissue microarrays used for FISH studies, and correlated
with the expression of a panel of 33 antibodies previously
analyzed.
Results We have found 13q34 amplification in 4.5% of breast
cancer samples, but the frequency increased to 8.1% in
BRCA1-associated tumors and to 20% in basal-like tumors.
Tumors with 13q34 amplification were associated with high
grade, estrogen receptor negativity, and expression of EGFR,
CCNE, CK5, and P-Cadherin, among other basal cell markers.
We have defined a 1.83 megabases minimal common region of
genomic amplification and carried out mRNA expression
analyses of candidate genes located therein, identifying CUL4A
and TFDP1 as the most likely target genes. Moreover, we have
confirmed that tumors with 13q34 amplification significantly
overexpress CUL4A and TFDP1 proteins. Tumors
overexpressing either CUL4A or TFDP1 were associated with
tumor proliferation and cell cycle progression markers.
Conclusions We conclude that 13q34 amplification may be of
relevance in tumor progression of basal-like breast cancers by
inducing overexpression of CUL4A and TFDP1, which are both
important in cell cycle regulation. Alternatively, as these genes
were also overexpressed in non-basal-like tumor samples, they
could play a wider role in cancer development by inducing tumor
proliferation.
Introduction
Breast cancer is a complex and heterogeneous disease, which
is one of the most frequent causes of cancer deaths in devel-
oped countries. Most of breast cancer cases are sporadic;
aCGH: array-based comparative genomic hybridization; Amp13q34: amplification at human chromosomal 13q34 region; BAC: Bacterial Artificial 
Chromosome; cCGH: conventional or chromosomal comparative genomic hybridization; CK: cytokeratin; ER: estrogen receptor protein; FFPE 
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around 5% of breast cancer patients are considered as having
hereditary breast cancer. These patients carry mutations in
either BRCA1 [1] or BRCA2 [2] genes, but there also are
familial breast cancer patients who do not carry mutations in
BRCA1/2  and presumably have mutations in another
unknown gene or gene(s) (termed non-BRCA1/2 or BRCAX
patients). Over the last decade, many studies have shown that
sporadic breast cancer can be grouped using molecular pro-
filing into subtypes: basal-like, HER2-overexpressing, luminal
A, and luminal B [3-5]. Researchers have identified molecular
features that differentiate sporadic breast cancer from each
group of familial breast cancers (BRCA1-,  BRCA2-, or
BRCAX-associated) [6-10]. However, our recent analyses
have pointed out the striking similarities between sporadic and
familial breast cancer in terms of the existence of breast can-
cer subtypes in both groups, as well as common patterns of
genomic aberrations [11]. This finding may emphasize the
interest in identifying molecular features that discriminate each
of the sporadic and familial breast cancer subtypes, rather
than comparing each group of familial breast cancer with spo-
radic tumors.
One common genomic aberration in breast cancer is high-
level amplification. These aberrations may activate a profound
increase in expression of genes within the amplification
boundaries, crucial for the origin and progression of breast
tumors. The most common regions of high-level amplification
in breast cancer are 17q12 (targeting ERBB2), 11q13
(CCND1), 8q24 (MYC); 8p11-p12; 17q22-25; and 20q13
[12,13]. Interestingly, recent genomic analyses have shown
that the chromosomal amplification sites tend to differ among
the molecular breast cancer subtypes as for instance: 17q12
in HER2-overexpressing tumors, 20q13 in luminal-B tumors,
11q13 in both luminal A and B tumors, or 13q34 in basal-like
tumors [5,11,14-16]. The definition of these chromosomal
aberrations may elucidate genes crucial for the origin and pro-
gression of each breast cancer subtype. Taking this into
account, we focused on a comprehensive characterization of
13q34 amplification (Amp13q34), a genomic aberration that
we have recently found to be associated with basal-like breast
cancers [11]. This amplification has been previously reported
in squamous cell carcinomas [17], adrenocortical carcinomas
[18], childhood medulloblastoma [19], hepatocellular carcino-
mas [20], and breast cancer [21], using conventional compar-
ative-genomic hybridization (cCGH). Genes proposed to be
the target genes of Amp13q34 include CUL4A,  LAMP1,
TFDP1, or GAS6 [20,22-26].
We have further characterized Amp13q34 in sporadic and
familial breast cancer and defined its overall frequency, as well
as its boundaries by fluorescence in situ hybridization (FISH)
and array-based comparative genomic hybridization (aCGH)
techniques. We have analyzed the gene- and protein-expres-
sion levels of candidate genes as well as their correlation with
clinical and immunohistochemical (IHC) features. We propose
that CUL4A and TFDP1 are likely the driver genes for this
genomic amplification, leading higher tumor aggressiveness
through deregulation of cell cycle.
Materials and methods
Patients and tumor samples
A total of 188 familial breast cancer patients belonging either
to families with at least three women affected with breast and/
or ovarian cancer, one of them diagnosed before 50 years of
age, or to families with women affected with breast and/or
ovarian cancer and at least one case of male breast cancer. All
patients were screened for point mutations and large rear-
rangements in the BRCA1/2 genes using standard methods
[27]. A series of 277 sporadic breast cancer samples came
from the Spanish National Cancer Center (Spain) (172 sam-
ples), the Cancer Center of Solca (Ecuador) (86 cases), and
the University of Pennsylvania (USA) (19). Written consent for
tumor analyses and publication was obtained from the patient
or their relative. This research study has been performed with
the approval of an ethics committee.
DNA isolation from formalin-fixed paraffin embedded 
tumor tissues
Genomic DNA isolation from formalin-fixed paraffin embedded
(FFPE) tumors was carried out as previously described [28].
Briefly, two 30-μm sections were obtained from FFPE tumors,
treated with xylene, incubated in Glycine Tris-EDTA and
NaSCN, and finally digested with proteinase K and purified
with phenol chloroform. All sections were previously examined
and dissected with a scalpel to ensure at least 70% content of
tumor cells.
Array-based comparative genomic hybridization (aCGH)
Comparative genomic hybridization was done onto the 1 meg-
abase (Mb) Bacterial Artificial Chromosome (BAC) clone array
platform developed at the University of Pennsylvania. In few
words, the platform is composed of 4134 BAC clones spaced
at 1 Mb intervals, including a direct coverage of approximately
400 known cancer genes [29]. DNA probe labeling, aCGH
protocol, and array data analysis have been described else-
where [28]. Briefly, normalized aCGH data were analyzed
using the Binary Segmentation algorithm implemented in the
Insilico CGH software [30]. This algorithm depicts genomic
segments showing estimative copy number values in log2ratio,
which are calculated from the mean log2ratio of all the clones
within that segment. As a result, it decreases both the dynamic
range of the hybridization and the high noise usually present in
hybridizations of DNA from FFPE tissues [31,32]. Therefore,
we considered those segments with log2ratio ≥ 0.1 as gains,
whereas those with log2ratio  ≤ -0.1 were categorized as
losses. Segments altered with DNA amplifications were con-
sidered when log2ratio ≥ 0.4. A collection of genomic imbal-
ances previously confirmed in breast cancer cell lines and
breast tumor samples allowed us to set these thresholds.Available online http://breast-cancer-research.com/content/11/6/R86
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Fluorescence in situ hybridization (FISH)
FISH analysis was carried out on the original group of six
tumor samples with Amp13q34 found in the aCGH studies to
verify their amplification levels. Then, we performed the FISH
study on two familial and three sporadic breast cancer tissue
microarrays (TMA) containing 156 and 258 breast tumor sam-
ples respectively, in order to quantify the Amp13q34 rate in a
larger collection. From the familial breast cancer series, 44
samples were already included in our aCGH analysis [28].
These TMA have been described elsewhere [9,33,34]. Briefly,
tumor areas of the breast tumor samples were carefully
selected from hematoxilin and eosin-stained sections and
delimited on the individual paraffin blocks. Then, two tissue
cores from the selected tumor area of each specimen were
obtained and included in the TMA.
The test FISH probe was composed of three BAC clones
mapping to the 13q34 chromosomal region, labeled with
dUTP-SpectrumOrange (Vysis, Inc. Downers Grove, IL, USA):
RP11-391H12 (AL136221.38, mid-position 113.96 Mb),
RP11-102K13 (AL160251.29, 114.09 Mb) and RP11-
230F18 (AL442125.13, 114.21 Mb). In addition, three BAC
clones from the 13q12.11 chromosomal region were used as
copy number reference for chromosome 13, labeled with
dUTP-SpectrumGreen (Vysis, Inc. Downers Grove, IL, USA):
RP11-301J16 (AL137001.23, 19.63 Mb), RP11-408E5
(AL139327.18, 19.77 Mb), and RP11-385E5 (AL356259.11,
19.92 Mb). FISH analysis was done according to Vysis'
instructions, with slight modifications. An average of 110 (50
to 200) well-defined nuclei was analyzed by scoring the
number of single copy 13q34 and 13q12.11 signals. We con-
sidered DNA amplification when > 50% of tumor cells showed
more than three times as many 13q34 signals as 13q12.11
copy signals.
RNA isolation from formalin-fixed paraffin embedded 
tissues and cDNA synthesis
Total RNA was obtained from six breast tumors with
Amp13q34 (three BRCA1-associated, one BRCA2-associ-
ated, one BRCAX-associated, and one sporadic breast tumor
samples) and one breast cancer cell line that also carried the
amplification (MDA-MB-157); as well as from 13 breast
tumors that did not exhibit DNA copy number changes at
13q34. Importantly, 13q34 DNA copy number status for all
tumoral specimens had been assessed by either aCGH or
FISH analyses. All tumor samples were FFPE material, and
RNA isolation was carried out as described before [35].
Briefly, a standard tissue sample deparaffinization was per-
formed using xylene and alcohols. Then, samples were incu-
bated in a digestion buffer (10 mM TrisHCl pH 8.0; 0.1 mM
EDTA; 2% SDS and 500 μg/ml proteinase K). Nucleic acids
were purified with standard phenol-chloroform-isoamyl alcohol
procedures, followed by a precipitation with isopropanol, gly-
cogen and sodium acetate. After DNase treatment (Ambion
Inc., Austin, TX, USA) at 37°C for 30 minutes, RNA was finally
processed for cDNA synthesis using M-MLV retrotran-
scriptase enzyme (Invitrogen, Carlsbad, CA, USA).
Quantitative real time polymerase chain reaction (qRT-
PCR) for mRNA expression
Assays were designed using the Roche Applied Science Uni-
versal Probe Library website [36] (Roche Diagnostics, Basel,
Switzerland) for all target genes and endogenous control (see
Additional file 1). qRT-PCR assays were set up in triplicates
and performed using the ABI Prism 7900HT Sequence Detec-
tion System (Applied Biosystems, Foster City, CA, USA). Rel-
ative expression was determined using the free access
software qBase [37] based on a modification of the classic
delta-delta Ct method that allows for PCR efficiency correc-
tion. Appropriate positive and negative controls including non-
retrotranscribed RNA for each sample were run for the exper-
iment.
Histology and immunohistochemistry
To associate genomic copy number aberration at 13q34 with
changes in protein levels of the candidate genes, we carried
out antibody specific staining on the same TMA used in the
FISH analyses.
IHC assays were performed by the Envision method (Dako,
Glostrup, Denmark) with a heat-induced antigen retrieval step.
TMA sections were immersed in 10 mM boiling sodium citrate
at pH 6.5 for two minutes in a pressure cooker. Between 150
and 200 cells per core were scored to determine the percent-
age of cells with positive nuclei or cytoplasm, depending upon
the marker. We evaluated the protein expression level for the
two candidate genes within Amp13q34 that were significantly
overexpressed in the qRT-PCR analyses: CUL4A and TFDP1.
As CUL4A expression in the cytoplasm was found in most of
cases, we delineated four levels of staining: 0 (null staining), 1
(low staining), 2 (medium staining), and 3 (strong staining),
which we grouped into negative (0), mid-level (1, 2) and posi-
tive (3) in subsequent analyses. TFDP1 is localized in the cell
nucleus, so the median percentage of positive nuclei in all
cases was used as the threshold to discriminate between neg-
ative (< 25%) or positive expression (≥ 25%). Tumor samples
with more than 60% of stained cells (the median percentage
of stained cells in only positive cases) were further categorized
as highly expressed for the association with Amp13q34.
Other proteins also were studied to establish potential associ-
ations. We had previously evaluated nuclear staining for estro-
gen receptor (ER), progesterone receptor (PR), p53, Ki-67,
cyclins D1, D3, E, and A; p16, p27, p21, CDK1, CDK2,
CDK4, Skp2, retinoblastoma protein (Rb), E2F1, E2F6,
MDM2, topoisomerase IIα, survivin, and CHEK2; cytoplasmic
staining for BCL2, vimentin, cytokeratin 5/6 (CK5/6), cytoker-
atin 8 (CK8), and cyclin B1; and membrane staining for E-cad-
herin, P-cadherin, B-catenin and G-catenin [34]. HER-2
expression was evaluated according to the four-category (0 toBreast Cancer Research    Vol 11 No 6    Melchor et al.
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3+) DAKO system proposed for the evaluation of the Her-
cepTest, and HER-2 expression of 3+ was the only value con-
sidered positive [34]. Antibodies, dilutions, suppliers, and
thresholds used for analyses are listed in Additional file 2.
Statistical analyses
In order to compare the mRNA expression levels between the
different groups (tumors with or without Amp13q34), we
applied the U-Mann Whitney test. We also determined asso-
ciations between tumor groups with both clinical features and
IHC markers using the chi square test, with the two-tailed
Fisher's exact test correction when needed. The statistical
software SPSS for Windows (SPSS, Inc., Chicago, IL, USA)
was used to perform these statistical comparisons.
Results
Frequency and genomic definition of the 13q34 
amplification
We have previously reported that about 5% of both familial
and sporadic breast cancers contain a high-level amplification
at 13q34 (Amp13q34) using chromosomal- and array-based
comparative genomic hybridization techniques (cCGH, and
aCGH, respectively) (Table 1 and Figure 1a) [21,28]. Now, we
have extended the study of the rate of Amp13q34 to a larger
cohort of 414 familial and sporadic breast cancer samples
using FISH technique. We have found that Amp13q34 is
present in around 4.5% of breast cancer samples (Figure 1b-
c), although the rate differs slightly among tumor classes,
being higher in BRCA1- (8.1%) than in BRCA2- or non-
BRCA1/2- (< 3.0%) associated cancers (Table 1). However,
these differences are not statistically significant, maybe due to
the low number of cases (data not shown). Noteworthy, the
level of amplification in this tumor cohort never exceeded a
13q34:13q12.11 copy ratio of seven, being the median ratio
of 4.5 as many 13q34 as 13q12.11 copy signals (Figure 1c).
This shows that 13q34 region, albeit that it is affected with
amplification, is not altered with the same magnitude as other
classical high-level DNA amplification sites, such as 17q12
(ERBB2). As expected, no tumor sample analyzed by both
cCGH/aCGH and FISH showed discrepancies in copy
number values.
To define the minimal common region of amplification, we
used data from a previous aCGH analysis [28]. A genomic
representation of those cases with Amp13q34 (three BRCA1-
, one BRCA2-, one BRCAX-, one sporadic-breast cancers
and one breast cancer cell line, MDA-MB-157) is shown in
Figure 2a. Chromosome 13 has two different genomic profiles
based on the start position of the genomic gain: a) loss from
the centromere to the 13q31 or 13q32 chromosomal band,
with gain or amplification extending from 13q31 to the tel-
omere (cases 1, 3, 4, 6, and 7); or b) copy neutral from the
centromere to 13q21 and gain or amplification from 13q21 to
the telomere (cases 2 and 5). A detailed analysis of the
genomic values on each of the studied cases allowed us to
narrow down the minimal common region of DNA amplification
to 1.83 Mb, mapping entirely within the 13q34 chromosomal
band. Two samples delimited the Amp13q34 region: tumor
#3 showed the Amp13q34 starting at RP11-520D2 (span-
ning 3.55 Mb, and 29 genes), whereas tumor #5 finally
defined the minimal 1.83 Mb region from RP11-375A8 to the
telomere that contains 22 genes (Figure 2b) (Table 2). As
tumor material was limited to carry out a whole characteriza-
tion of all the genes therein located, we selected those related
to tumorigenesis or cell transformation according to either pre-
vious studies or their hypothetical function. Our final list of
selected genes included: ARHGEF7,  ATP11A,  MCF2L,
CUL4A,  LAMP1, GRTP1, DCUN1D2,  TFDP1,  GAS6,
RASA3, and CDC16  (bold genes in Table 2). Although
ARHGEF7 is not located within the boundaries of the 1.83 Mb
region, it was selected to check a possible correlation for
those genes located outside the minimal region, but inside the
Figure 1
Genomic definition of the human 13q34 amplification I Genomic definition of the human 13q34 amplification I. (a) Chromosome 13 genomic profiles by conventional-comparative genomic hybridization 
(cCGH) of four breast cancer cases analyzed in a previous study by our group [21]. (b) FISH assays, detecting the 13q34 region (red probe) and 
the 13q12.11 region as a reference (green probe), show amplification at the 13q34 region in nuclei cell from a breast cancer sample (left, seven to 
eight red and one to two green signals) and in a metaphase of the MDA-MB-157 breast cancer cell line (right, six red and two green signals). (c) 
Boxplots displaying the range of copy signals for 13q12.11 (green box) and 13q34 (red box) in those cases with Amp13q34 found in our FISH 
screening.Available online http://breast-cancer-research.com/content/11/6/R86
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3.55 Mb defined by the case #3. Noteworthy, the 13q34 FISH
probe used in this study covered CUL4A, LAMP1, GRTP1,
DCUN1D2, and TFDP1 (Figure 2 and Table 2).
Analyses of the mRNA expression level for the candidate 
genes by qRT-PCR
Once the minimal amplification site had been delineated, qRT-
PCR was carried out to determine the mRNA expression level
of each of the 11 candidate genes, comparing two cohorts of
FFPE samples: tumors with Amp13q34 (six tumor samples
and MDA-MB-157), and tumors without any genomic aberra-
tion at 13q34 region (13 cases). ARHGEF7 and ATP11A
showed a non-statistically significant trend to be overex-
pressed in Amp13q34 tumors (P = 0.242 and P = 0.191,
respectively); whereas GAS6 and RASA3 had non-significant
tendencies to be downregulated in tumors with Amp13q34 (P
= 0.285 and P = 0.052, respectively) (Figure 3). Nevertheless,
two genes had significant association between amplification
and overexpression: CUL4A (P = 0.007) and TFDP1 (P =
0.019) (Figure 3). At this point, we focused on these two
genes as candidate drivers of the 13q34 amplification.
Correlation with protein expression levels and other 
immunohistochemical features
We performed immunohistochemical analyses of the two can-
didate genes (CUL4A and TFDP1) on a set of 414 breast can-
cer samples on TMAs, previously analyzed by FISH (see
above). Interestingly, the 75% of the tumors with Amp13q34
showed a strong staining for CUL4A, compared with 34.3%
of the tumors without Amp13q34, but overexpressing CUL4A
(P = 0.010) (Figure 4a-c and Table 3). A significant associa-
tion was also found between Amp13q34 and TFDP1, since
the 92.3% of the tumors with Amp13q34 (12/13) presented
TFDP1 overexpression (P = 0.004), whereas the 51.9% of the
tumors without Amp13q34 overexpressed TFDP1 (Figure 4d-
f and Table 3). Furthermore, when considering a higher per-
centage (> 60%) of TFDP1 positive cells as the threshold,
76.9% of Amp13q34 tumors had TFDP1 overexpression as
compared with 20.1% of the tumors without Amp13q34 (P =
< 0.001) (Table 3). Interestingly, 60% of tumors with
Amp13q34 co-overexpressed both CUL4A and TFDP1 (6 out
of 10 tumors), although it was not statistically significant
maybe due to the low number of samples (data not shown).
Altogether, these findings demonstrated that Amp13q34 was
significantly associated with a higher expression level of both
CUL4A and TFDP1, but given that there are cases without the
amplification showing protein overexpression, Amp13q34
was not the exclusive mechanism causing overexpression of
these genes.
In addition, we associated Amp13q34 with other immunohis-
tochemical and clinical tumor features previously analyzed on
a subset of the sample set (260 out of 414 samples) [33,34].
We observed that tumors with Amp13q34 were characterized
by high histological grade; an absence of expression of ER,
PR, CCND1, RB, p16, and CK8; and an overexpression of Ki-
67, EGFR, P-Cadherin, G-catenin, CCNE, CCNB1, SKP2,
survivin, vimentin, and CK5 (Table 4). As most of these mark-
ers are associated with basal-like phenotype of breast cancer,
these associations may be due to the unique presence of the
Amp13q34 in basal-like tumors as we previously reported
[11]. CUL4A-overexpressing tumors had higher grade,
absence of expression of PR and BCL2, and a higher percent-
age of cases expressing EGFR, P-Cadherin, CCNB1, SKP2,
and CK5; when compared with tumors that did not overex-
press CUL4A (Table 4). Last, TFDP1-overexpressing tumors
were associated with overexpression of CCNE, CCNB1, and
p16 (Table 4). However, no significant association was found
between TFDP1 and CUL4A expression levels when studying
the overall breast cancer sample set (data not shown). These
associations support that the overexpression of CUL4A and
TFDP1, even though it is correlated with Amp13q34, is not
exclusive of basal-like tumors, but still relates to higher tumor
aggressiveness.
Table 1
DNA amplification rates at the region 13q34 in different analyses performed by our group
DNA amplification rate % (n)
Chromosomal region Analysis BRCA1 BRCA2 Non-BRCA1/2 Sporadic Total
13q31-q34 cCGH* 11.6 (3/26) 5.6 (1/18) 0 (0/36) - 5.0 (4/80)
13q34 aCGH** 15.8 (3/19) 4.2 (1/24) 0 (0/31) 10.5 (2/19) 6.5 (6/93)
13q34 FISH+ 9.5 (2/21) 0 (0/14) 4.8 (3/66) 4.2 (8/192) 4.4 (13/293)
Total 8.1 (3/37) 2.6 (1/38) 3.3 (3/92) 4.7 (10/211) 4.5 (17/378)
The percentage of cases with Amp13q34 is shown.
*Melchor et al., 2005 [21]. Genomic amplification is considered when CGH ratio > 1.5 (see Figure 1a).
**Melchor et al., 2007 [28]. Amplification is regarded as genomic segments with log2ratio ≥ 0.4.
+Current study. Numbers correspond to cases in the tissue microarrays that were analyzable. We considered amplification when in tumor areas > 
50% tumor cells showed > 3 times as many 13q34 signals as 13q12.11 copy signals.Breast Cancer Research    Vol 11 No 6    Melchor et al.
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Discussion
In the present study, we have characterized the genomic
amplification at the human 13q34 chromosomal region in
familial and sporadic breast cancer cases. We have defined a
minimal common region of amplification using FISH and
aCGH techniques. Moreover, we have characterized the gene
and protein expression levels of eleven candidate genes within
the region using qRT-PCR and immunohistochemistry assays.
The correlations that we have found suggest TFDP1  and
CUL4A as likely drivers of this genomic aberration.
Amp13q34 previously has been reported in breast cancer
[22,23] as well as in squamous cell carcinomas, adrenocorti-
cal carcinomas, childhood medulloblastoma, and hepatocellu-
lar carcinomas [17-20]. In our analyses, Amp13q34 is a low
frequent genomic event in overall breast cancer (around 4.5%)
but the rate increases when analyzing BRCA1-associated
breast cancer (8.1%) (Table 1) or basal-like tumors (about
20%) [11]. Although this increase is not statistically significant
(data not shown), it is in agreement with previous analyses that
describe genomic gains/amplifications at 13q34 in ER-nega-
Figure 2
Genomic definition of the human 13q34 amplification II Genomic definition of the human 13q34 amplification II. (a) Genomic pattern of chromosome 13 by array-based comparative genomic hybridization 
(aCGH) in seven breast cancer samples (six familial breast tumors from the Spanish National Cancer Research Center, one sporadic breast tumor 
sample from the University of Pennsylvania, and MDA-MB-157 cell line) from centromere (top, CEN) to telomere (bottom, TEL). An idiogram showing 
chromosomal bands is depicted on the left. Each row represents a BAC array-clone sorted by their position in the UCSC Genome Browser (Human 
Feb 2009, assembly (hg 19)). Each clone is colored for each sample according to its level of genomic copies: loss (red), normal (white), gain (light 
green), amplification (dark green). Grey cells reflect clone data rejected after quality tests for signal intensity and replicate reproducibility. The green 
and red stars correspond to the location of the BAC probes used for FISH analyses. (b) aCGH genomic pattern of the 13q31-q34 chromosomal 
region. The BAC clone name and mid-position Mb is displayed. Colors mean the same as in A. The red star shows names and locations of the FISH 
clones used for the 13q34 probe. The striped dark green box represents the 1.83 Mb minimal common region of DNA amplification within the 
13q34 site. A list of genes located within this minimal region is supplied in Table 2.Available online http://breast-cancer-research.com/content/11/6/R86
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Table 2
List of genes located in the minimal common region of amplification at 13q34
Gene Name* Reference Sequence Chromosome location 
(start pb - end pb)**
Name Additional information
ANKRD10 NM 017664 111530888-111567416 ankyrin repeat domain 10
ARHGEF7 NM 145735.2 111767624-111947542 Rho guanine nucleotide 
exchange factor (GEF) 7
Rho GTPase
C13orf16 NM 152324.1 111973015-111996593 chromosome 13 open reading 
frame 16
SOX1 NM 005986.2 112721913-112726020 SRY (sex determining region 
Y)-box 1
Transcription factor involved in the 
regulation of embryonic development 
and in the determination of the cell 
fate
C13orf28 NM 145248.3 113030669-113089001 chromosome 13 open reading 
frame 28
TUBGCP3 NM 006322.4 113139328-113242481 tubulin, gamma complex 
associated protein 3
C13orf35 NM 207440.1 113301358-113338811 chromosome 13 open reading 
frame 35
ATP11A NM 032189.3 113344643-113541480 ATPase, class VI, type 11A Integral membrane ATPase
MCF2L NM 001112732.1 113622757-113752862 MCF.2 cell line derived 
transforming sequence-like
F7 NM 000131.3 113760105-113774994 coagulation factor VII (serum 
prothrombin conversion 
accelerator)
Coagulation factor. Defects in this 
gene can cause coagulopathy
F10 NM 000504.3 113777113-113803841 coagulation factor X Coagulation factor. Mutations of this 
gene result in factor X deficiency, a 
hemorrhagic condition of variable 
severity.
PROZ NM 003891.1 113812968-113826694 protein Z, vitamin K-dependent 
plasma glycoprotein
PCID2 NM 018386.2 113831925-113863029 PCI domain containing 2
CUL4A NM 001008895.1 113863931-113919391 cullin 4A
LAMP1 NM 005561.3 113951469-113977741 lysosomal-associated 
membrane protein 1
Membrane glycoprotein. It may 
also play a role in tumor cell 
metastasis
GRTP1 NM 024719.2 113978506-114018463 growth hormone regulated 
TBC protein 1
ADPRHL1 NM 138430.3 114076586-114107839 ADP-ribosylhydrolase like 1 Reversible posttranslational 
modification used to regulate protein 
function
DCUN1D2 NM 001014283.1 114110134-114145023 DCN1, defective in cullin 
neddylation 1, domain 
containing 2 (S. cerevisiae)
TMCO3 NM 017905.4 114145308-114204542 transmembrane and coiled-coil 
domains 3
TFDP1 NM 007111.4 114239056-114295786 transcription factor Dp-1 Transcription factor that 
heterodimerizes with E2F proteins 
to enhance their DNA-binding 
activity and promote transcription 
from E2F target genes.
ATP4B NM 000705.2 114303123-114312501 ATPase, H+/K+ exchanging, 
beta polypeptide
Encodes the beta subunit of the 
gastric H+, K+-ATPase
GRK1 NM 002929.2 114321597-114438636 G protein-coupled receptor 
kinase 1
Ser/Thr protein kinase that 
phosphorylates rhodopsin and 
initiates its deactivation. Defects in 
GRK1 are known to cause Oguchi 
disease 2Breast Cancer Research    Vol 11 No 6    Melchor et al.
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tive tumors, basal-like tumors, BRCA1-associated breast can-
cers, and medullary carcinomas [10,16,38,39]. Furthermore,
we found that Amp13q34 is associated with a high histologi-
cal grade, hormonal receptor negativity, and an overexpres-
sion of basal cytokeratins, cell cycle promoters (CCNE,
CCNB1) and EGFR, among other markers (Table 4). These
findings suggest that Amp13q34 is biologically important in
the progression of basal-like breast cancers. Although a
screening in a larger basal-like tumor cohort would be needed;
once the prevalence of Amp13q34 is confirmed in this breast
tumor phenotype, this genomic aberration could be used both
as a clinical marker and as a therapeutic target for Amp13q34
tumors.
As far as we know, this is the first high-resolution genomic
characterization of the amplification at the human 13q34 chro-
mosomal site. We narrowed down the minimal common region
of Amp13q34 to 1.83 Mb, which included 22 genes, of which
11 may be related to tumorigenesis: ARHGEF7, ATP11A,
MCF2L,  CUL4A,  LAMP1,  GRTP1,  DCUN1D2,  TFDP1,
GAS6, RASA3, and CDC16  (Figure 2 and Table 2). In a
recent study of mammary tumors arising in a p53-null mouse
model, a genomic amplification at mouse chromosomal 8A1
region, syntenic to the human 13q34 region, was defined with
a high-resolutive genomic BAC array. The authors reported
two minimal clusters of amplification that also covered the
aforementioned genes. In addition, they described amplifica-
tion of CUL4A (25.7%), LAMP1 (13.5%), TFDP1 (31.1%),
and GAS6 (13.5%) by DNA qRT-PCR on a set of 74 human
breast carcinomas [22]. Noticeably, the amplification and
overexpression of CUL4A was also reported in primary breast
cancers a few years ago [23]. All these findings support a role
for Amp13q34 in human breast cancer, likely through the
increased expression of the genes located therein.
Based on the correlations observed in this study, CUL4A and
TFDP1 are suggested to be the target genes for this genomic
amplification. Both their mRNA (Figure 3) and proteins (Figure
4, and Table 3) are significantly overexpressed in breast
tumors with Amp13q34 when compared with breast tumors
without 13q34 genomic alterations. Therefore, our data sup-
port the importance of these genes as targets for the amplifi-
cation, consistent with previous findings not only in breast
cancer [22], but also in hepatocellular carcinomas [20].
CUL4A is a member of the cullin protein family and composes
the multifunctional ubiquitin-protein ligase E3 complex [40].
Our results suggest that CUL4A may play a role in breast can-
LOC100130386 NR 028064.1 114451484-114454062 hypothetical protein 
LOC100130386
GAS6 NM 000820.2 114523524-114567046 growth arrest-specific 6 Gamma-carboxyglutamic acid 
(Gla)-containing protein thought to 
be involved in the stimulation of 
cell proliferation, and may play a 
role in thrombosis
FLJ44054 NR 024609.1 114586610-114626485 hypothetical protein 
LOC643365
RASA3 NM 007368.2 114747195-114898095 RAS p21 protein activator 3 Member of the GAP1 family of 
GTPase-activating proteins. The 
gene product stimulates the 
GTPase activity of normal RAS p21 
but not its oncogenic counterpart. 
Acting as a suppressor of RAS 
function, the protein enhances the 
weak intrinsic GTPase activity of 
RAS proteins resulting in the 
inactive GDP-bound form of RAS, 
thereby allowing control of cellular 
proliferation and differentiation.
CDC16 NM 003903.3 115000362-115038150 cell division cycle 16 
homolog (S. cerevisiae)
Component protein of the APC 
complex, a cyclin degradation 
system that governs exit from 
mitosis
UPF3A NM 080687.1 115047078-115071281 UPF3 regulator of nonsense 
transcripts homolog A (yeast)
Component of a post-splicing 
multiprotein complex involved in both 
mRNA nuclear export and mRNA 
surveillance
ZNF828 NM_032436.2 115079965-115092802 zinc finger protein 828
*Genes in bold were selected for candidate gene analyses by qRT-PCR.
**Gene locations are according to UCSC Genome Browser (Human Feb 2009, assembly (hg 19)).
Table 2 (Continued)
List of genes located in the minimal common region of amplification at 13q34Available online http://breast-cancer-research.com/content/11/6/R86
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Figure 3
Gene expression analysis by qRT-PCR of the eleven candidate genes located in the minimal common regions of Amp13q34 Gene expression analysis by qRT-PCR of the eleven candidate genes located in the minimal common regions of Amp13q34. Relative expression lev-
els of the candidate genes in two sample cohorts: breast tumors with no genomic aberration at 13q34 (grey), and breast tumors with Amp13q34 
(black). The expression of the candidate genes was evaluated by real-time quantitative RT-PCR and normalized with a housekeeping gene (ACTB). 
P values are shown for those genes with statistically significant differences when comparing the two groups in a U-Mann Whitney Test (P < 0.05).
Figure 4
Immunohistochemical staining for CUL4A (A-C) and TFDP1 (D-F) in tumors with and without Amp13q34 Immunohistochemical staining for CUL4A (a-c) and TFDP1 (d-f) in tumors with and without Amp13q34. (a) Null CUL4A staining in a non-amplifier 
tumor sample. (b) Moderate CUL4A staining in a non-amplifier tumor sample. (c) Strong CUL4A staining in a tumor with the Amp13q34. (d) Nega-
tive TFDP1 expression in a tumor without Amp13q34. (e) and (f) Strong TFDP1 expression in tumors with Amp13q34, the arrow in (f) points out the 
absence of expression in a lymphocyte infiltrate compared with the breast tumor cells.Breast Cancer Research    Vol 11 No 6    Melchor et al.
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cer progression, based on its amplification and significant
overexpression, previously reported in breast malignancies
[22,23], as well as in other carcinomas [20]. It has been
shown that CUL4A could contribute to tumor malignancy
mediating the activity of tumor suppressors and thus, altering
cell cycle checkpoints [41-44]. Moreover, a recent study has
reported that breast cancer patients with strong expression of
CUL4 had a significantly shorter overall and disease-free sur-
vival [25]. In our analysis, CUL4A overexpressing tumors were
characterized by a high histological grade, an absence of PR
and BCL2 expression, and a high expression of cell cycle pro-
moters (cyclin B and SKP2), cell signaling components
(EGFR), basal cytokeratins (CK5), and cell adhesion proteins
(P-cadherin) (Table 4), suggesting high cell proliferation and
tumor aggressiveness. As some of these features are basal-
cell markers (such as EGFR, CK5, P-Cadherin), CUL4A may
play an important role in the biology of basal-like breast can-
cers. Furthermore, our results suggest the role for CUL4A as
part of the development of breast tumors in general, mainly
through deregulation of cell cycle checkpoints.
TFDP1 is a heterodimerization partner for members of the E2F
family of transcription factors. E2F1/TFDP1 forms a complex
involved in cell cycle progression by the regulation of expres-
sion of cell cycle promoters (cyclin A, cyclin E, CDK2) [45]. In
our study, breast tumors overexpressing TFDP1 had high
expression of p16, cyclin E and cyclin B1 (Table 4), as
described in hepatocellular carcinoma [20]. These associa-
tions point out a deregulation of the cell cycle in these tumors.
However, overexpression of TFDP1 did not correlate with
altered expression levels either of its protein partner, E2F1, or
one of the E2F1/TFDP1 regulators, RB, in our tumor cohort
(data not shown). The lack of correlation between TFDP1 and
E2F1 expression suggests that TFDP1 may have a function in
addition to gene transcription regulation and cell cycle pro-
gression in breast cancer. This discordance between E2F1
and TFDP1 protein levels was also described in non-Hodgkin
lymphomas [46] and in hepatocellular carcinomas, where only
TFDP1 overexpression was associated with a larger tumor
size [26]. Additionally, Abba and colleagues analyzed publicly
available human breast cancer mRNA expression datasets
and found significant associations of TFDP1 overexpression
with shorter overall survival, relapse-free survival, and metasta-
sis-free interval [22]. Moreover, TFDP1 overexpression has
been related to progression of hepatocellular carcinomas [26],
and together with activated HA-RAS, causes oncogenesis in
rat embryo fibroblasts [47]. Thus, TFDP1 is not only a strong
candidate to drive Amp13q34, but also a gene involved in dif-
ferent components of tumorigenesis, causing higher tumor
aggressiveness and a poor patient prognosis. Further func-
tional analyses to elucidate its potential role in breast cancer
oncogenesis need to be performed.
The other candidate genes that we studied (ARHGEF7,
ATP11A,  MCF2L,  LAMP1,  GRTP1,  DCUN1D2,  GAS6,
RASA3 and CDC16) did not demonstrate overexpression in
Amp13q34 tumors, although non-significant trends were
found for overexpression of ARHGEF7  and  ATP11A, and
downregulation of GAS6 and RASA3 (Figure 3). However,
the lack of significant correlations for these genes between
copy number and expression in our dataset should not rule out
their possible role in breast cancer. For example, a recent arti-
cle associated expression of GAS6 with indicators of good
prognosis such as progesterone receptor positivity, small
tumor size, low grade, and young patient age [24]. These
tumor features do not correspond to the ones found in
Amp13q34 tumors, which are mainly ER and PR negative
(Table 4); thus, GAS6  may not be the target gene in the
Amp13q34, but may still play a role in other breast cancers.
Table 3
Correlation of the presence/absence of Amp13q34 with the protein expression levels of CUL4A and TFDP1
CUL4A expression TFDP1 expression
CUL4A CUL4A TFDP1 TFDP1
13q34 -ve +ve -ve mid +ve -ve +ve -ve +ve1 +ve2
No amp 155 (65.7) 81 (34.3) 4 (1.7) 151 (64.0) 81 (34.3) 115 (48.1) 124 (51.9) 115 (48.1) 76 (31.8) 48 (20.1)
Amp 3 (25.0) 9 (75.0) 0 (0) 3 (25.0) 9 (75.0) 1 (7.7) 12 (92.3) 1 (7.7) 2 (15.4) 10 (76.9)
P-values P = 0.010 P = 0.017* P = 0.004* P = < 0.001*
Each cell shows the number of samples and the percentage in the series between brackets.
CUL4A expression levels: a) -ve (negative) (null, low and medium staining) and +ve (positive) (strong staining); b) negative (null staining), mid (low 
and medium staining) and positive (strong staining).
TFDP1 expression levels: a) negative (< 25%) and positive (> 25%); b) negative (< 25% stained cells), +ve1 (positive) (between 25-60% stained 
cells), +ve2 (positive) (> 60% stained cells).
*P values from the Chi square of Pearson.
Amp = amplification.Available online http://breast-cancer-research.com/content/11/6/R86
Page 11 of 14
(page number not for citation purposes)
Table 4
Protein marker associations between tumors with/without Amp13q34, CUL4A expression, or TFDP1 expression
Clinical & IHC feature 13q34 Amplification CUL4A expression TFDP1 expression
Absence Presence P Negative Positive P Negative Positive P
Grade
1 42 (32.1) 0 0.002* 26 (40.6) 10 (19.2) 0.010* 12 (32.4) 27 (33.3) NS*
2 40 (30.5) 0 19 (29.7) 13 (25.0) 11 (29.7) 22 (27.2)
3 49 (37.4) 8 (100) 19 (29.7) 29 (55.8) 14 (37.8) 32 (39.5)
ER
Negative 56 (35.4) 8 (88.9) 0.002 30 (36.6) 29 (48.3) NS 24 (46.2) 35 (38.0) NS
Positive 102 (64.6) 1 (11.1) 52 (63.4) 31 (51.7) 28 (53.8) 57 (62.0)
PR
Negative 68 (47.2) 8 (88.9) 0.018 30 (43.5) 37 (62.7) 0.034 20 (48.8) 47 (52.3) NS
Positive 76 (52.8) 1 (11.1) 39 (56.5) 22 (37.3) 21 (51.2) 42 (47.7)
BCL2
Negative 82 (56.9) 8 (88.9) 0.082 37 (53.6) 42 (71.2) 0.047 29 (70.7) 52 (58.4) NS
Positive 62 (43.1) 1 (11.1) 32 (46.4) 17 (28.8) 12 (29.3) 37 (41.6)
Ki-67
0-5% 68 (47.2) 1 (11.1) < 0.001* 35 (50.7) 22 (37.3) NS* 22 (53.7) 35 (39.3) NS*
6-25% 56 (38.9) 1 (11.1) 24 (34.8) 20 (33.9) 13 (31.7) 32 (36.0)
> 25% 20 (13.9) 7 (77.8) 10 (14.5) 17 (28.8) 6 (14.6) 22 (24.7)
EGFR
Negative 181 (90.0) 4 (40.0) < 0.001 122 (91.7) 57 (80.3) 0.024 94 (91.3) 89 (85.6) NS
Positive 20 (10.0) 6 (60.0) 11 (8.3) 14 (19.7) 9 (8.7) 15 (14.4)
Cadherin P
Negative 128 (92.1) 3 (33.3) < 0.001 63 (95.5) 46 (79.3) 0.011 37 (94.9) 74 (86.0) NS
Positive 11 (7.9) 6 (66.6) 3 (4.5) 12 (20.7) 2 (5.1) 12 (14.0)
G-Catenin
Negative 106 (79.1) 4 (44.4) 0.031 59 (86.8) 43 (75.4) NS 36 (90.0) 69 (78.4) NS
Positive 28 (20.9) 5 (55.5) 9 (13.2) 14 (24.6) 4 (10.0) 19 (21.6)
Cyclin D1
Negative 67 (47.2) 8 (88.9) 0.018 32 (47.1) 27 (46.6) NS 17 (42.5) 42 (47.7) NS
Positive 75 (52.8) 1 (11.1) 36 (52.9) 31 (53.4) 23 (57.5) 46 (52.3)
Cyclin E
Negative 103 (72.5) 2 (22.2) 0.004 50 (73.5) 34 (58.6) 0.090 32 (80.0) 53 (60.2) 0.043
Positive 39 (27.5) 7 (77.8) 18 (26.5) 24 (41.4) 8 (20.0) 35 (39.8)
Cyclin B1
Negative 111 (80.4) 4 (44.4) 0.024 57 (86.4) 40 (70.2) 0.045 37 (92.5) 61 (72.6) 0.010
Positive 27 (19.6) 5 (55.6) 9 (13.6) 17 (29.8) 3 (7.5) 23 (27.4)Breast Cancer Research    Vol 11 No 6    Melchor et al.
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Conclusions
In summary, we have characterized a 1.83 Mb minimal com-
mon region of amplification at 13q34 that may play a crucial
role in the development of basal-like breast cancers. Analyses
of larger series of this tumor subtype will allow us to confirm
the specificity of this aberration and, importantly, its possible
use as a clinical marker of basal-like tumors. This genomic
aberration could facilitate the tumor progression through the
overexpression of driver/target genes such as TFDP1  and
CUL4A, which are overexpressed not only in Amp13q34
tumors, but also in other breast cancer samples characterized
by a high cell proliferation and aggressiveness. Therefore, fur-
ther functional analyses should be performed to demonstrate
their potential oncogenic roles, so that the development of
pharmaceutical suppressors of CUL4A or TFDP1 activity
could provide a therapeutic target for tumors overexpressing
these proteins.
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